XBIO - xeneticbio.com Company Buyout Price

Brandmark of Xenetic Biosciences, Inc. (XBIO)

Xenetic Biosciences (XBIO) is developing advanced oncology platforms, leveraging a global network of biocomponents to protect its developments from disruptions. Demand for such vaccines is independent of economic cycles, making the asset inflation-resistant. This price chart on GURU.Markets shows that the Enterprise Value is -1.66. The company is currently in the pre-commercial stage, financing its research through grants and equity issuance.

Xenetic Biosciences (XBIO) Enterprise Value: for the period 11/23/2025 - 10/31/2026

Summary analytical data breakdowns for Xenetic Biosciences, Inc. (XBIO)

- stock price and consensus target price:
Price Chart Xenetic Biosciences Inc.|XBIO - Analyst Consensus Forecast
- market capitalization statistics:
Market Capitalization Xenetic Biosciences|XBIO - Total Company Value
- balance sheet equity data:
Net Asset Value per Share Xenetic Biosciences|XBIO - Book Capitalization|Market Cap to Net Assets Ratio xeneticbio.com|XBIO - Company Total Assets
- debt level and financial liquidity data:
Total Debt to Capital Xenetic Biosciences|XBIO - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Xenetic Biosciences Inc.|XBIO - Company Aggregate Debts|Debt to Book Value Xenetic Biosciences|XBIO - Company Long-Term Debts|Short-Term Debt Xenetic Biosciences|Intermediate Coverage Ratio xeneticbio.com
- earnings and market multiples details:
XBIO - Net Income
Summary company analytics:XBIO - Xenetic Biosciences
Original product of Xenetic Biosciences

Enterprise value combines market capitalization with net debt to determine the actual cost of a full business buyout. By analyzing the total market valuation of the business at -1.66, an investor can identify asset undervaluation, which is critical for Xenetic Biosciences (XBIO), whose current value is based not on profit, but on the potential for oncology drug development and the volume of raised capital.

Who Xenetic Biosciences competes with

BeiGene Ltd. - Total Company Value|Halozyme Inc. - Enterprise Value|Company Buyout Price Revolution Medicines Corp RVMD|Ascentage Pharma Group (AAPG) - Total Company Value|Total Enterprise Value cgoncology.com (CGON)|URGN (UroGen Pharma) - Enterprise Value|Real Price to Acquire Entire Company Bicara Therapeutics Inc (BCAX)|Enterprise Value PSNL|Enterprise Value Erasca Oncology (ERAS)|Total Company Value Delcath Systems, Inc. DCTH|YMAB: Business Value|Aura Biosciences - Enterprise Value|Candel Therapeutics (CADL) - Real Price to Acquire Entire Company|ARAY: Enterprise Value|Total Enterprise Value SELLAS Life Sciences Group (SLS)|Total Company Value Actuate Therapeutics, Inc.|CTOR: Value Adjusted for Debt and Cash|Real Price to Acquire Entire Company HURA (TuHURA Biosciences, Inc.)|TARA (Protara Therapeutics Inc) - Value Adjusted for Debt and Cash|Enterprise Value FATE (Fate Therapeutics Corp)|WHWK - Real Price to Acquire Entire Company|TCRX: Real Price to Acquire Entire Company|CSBR - Enterprise Value|xbiotech.com (XBIT) - Total Company Value|CEL-SCI - Value Adjusted for Debt and Cash|OSTX (OS Therapies Inc) - Enterprise Value|Total Enterprise Value radiopharmtheranostics.com RADX|Real Price to Acquire Entire Company ARTV (Artiva Biotherapeutics, Inc.)|adlainortye.com - Business Value|Enterprise Value VERU (Veru)|Tempest Therapeutics Inc (TPST) - Total Enterprise Value|XLO - Total Company Value|RENB (Renovaro Inc.) - Business Value|MURA: Enterprise Value|Total Enterprise Value Kairos Pharma (KAPA)|Real Price to Acquire Entire Company OKUR|GDTC (CytoMed) - Aggregate Business Value|Enterprise Value CRIS|Company Buyout Price apollomicsinc.com|Enterprise Value THAR (Tharimmune, Inc.)|ADVB - Real Price to Acquire Entire Company|GNPX: Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash CLDI (Calidi Biotherapeutics)|SBFM: Enterprise Value|SLRX (Salarius Pharma) - Total Company Value|PPBT (Purple Biotech) - Enterprise Value|AON (AONC) - Company Buyout Price|Total Company Value BeiGene (BGNE)|CKPT - Total Enterprise Value|Total Company Value Elevation Oncology ELEV|Company Buyout Price iCAD Inc. (ICAD)|Ikena - Enterprise Value|notablelabs.com (NTBL) - Real Price to Acquire Entire Company|VIRX: Enterprise Value|MOR - Company Buyout Price|NAYA (NAYA Bio) - Enterprise Value|Total Enterprise Value Ascentage AAPGV